Protagonist Therapeutics ... (PTGX)
NASDAQ: PTGX
· Real-Time Price · USD
75.73
-1.95 (-2.51%)
At close: Oct 16, 2025, 3:59 PM
74.60
-1.49%
After-hours: Oct 16, 2025, 07:52 PM EDT
-2.51% (1D)
| Bid | 74 |
| Market Cap | 4.71B |
| Revenue (ttm) | 203.63M |
| Net Income (ttm) | 52.04M |
| EPS (ttm) | 0.73 |
| PE Ratio (ttm) | 103.74 |
| Forward PE | n/a |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 78.49 |
| Volume | 1,478,603 |
| Avg. Volume (20D) | 1,056,603 |
| Open | 77.83 |
| Previous Close | 77.68 |
| Day's Range | 74.62 - 78.00 |
| 52-Week Range | 33.31 - 93.25 |
| Beta | 2.20 |
| Ex-Dividend Date | n/a |
About PTGX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PTGX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PTGX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsProtagonist Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 days ago
+29.77%
Protagonist Therapeutics shares are trading higher...
Unlock content with
Pro Subscription
7 months ago
+45.89%
Protagonist Therapeutics shares are trading higher after the company announced topline results from its Phase 2b ANTHEM-UC study of icotrokinra in ulcerative colitis. The study met its primary endpoint in all dose groups evaluated.
